Financial Performance - In 2023, the basic earnings per share reached RMB 6.81, representing a 37.30% increase compared to RMB 4.96 in 2022[29] - The net profit attributable to shareholders of the listed company increased by over 30%, driven by strong market recognition and enhanced product competitiveness[30] - The weighted average return on net assets rose to 26.43%, an increase of 4.21 percentage points from 22.22% in the previous year[29] - The diluted earnings per share also stood at RMB 6.81, reflecting the same growth rate as the basic earnings per share[29] - The net profit after deducting non-recurring gains and losses was RMB 6.40 per share, a 42.22% increase from RMB 4.50 in 2022[29] - The company's operating revenue for 2023 reached ¥1,187,204,459.56, representing a 32.43% increase compared to ¥896,500,382.30 in 2022[38] - Net profit attributable to shareholders was ¥492,431,974.71, a 37.98% increase from ¥356,878,470.69 in the previous year[38] - The net profit after deducting non-recurring gains and losses was ¥462,198,067.66, up 42.74% from ¥323,794,022.99 in 2022[38] - Operating profit reached CNY 573.85 million, up 38.21% compared to the previous year[70] - The company achieved total operating revenue of CNY 1,187.20 million, a year-on-year increase of 32.43%[93] - Net profit attributable to shareholders was CNY 492.43 million, reflecting a growth of 37.98% year-on-year[93] Research and Development - The company's R&D investment accounted for 21.94% of operating revenue, an increase of 2.72 percentage points from 19.22% in 2022[29] - The company invested ¥26,043.75 million in R&D, accounting for 21.94% of its operating revenue[41] - The total number of R&D personnel increased to 266, accounting for 29.30% of the total workforce, with 57.14% holding master's degrees or higher[46] - Continuous investment in R&D is being emphasized to drive innovation and improve market acceptance of new products[69] - The company is actively investing in research and development to enhance its product offerings and maintain a competitive edge in the market[165] - The company plans to accelerate the launch of several new products, including a new generation of bare balloons and various aortic products, with approvals expected within the year[178] - Research and development investments increased by 30%, totaling $75 million, focusing on advanced medical technologies[188] - The company is investing $200 million in R&D for new technologies aimed at enhancing product features and user experience[200] Market Expansion and Sales - The company is focusing on expanding its marketing channels in lower-tier cities to enhance market penetration and product coverage[43] - Overseas sales revenue increased by over 55% compared to the same period last year, with products sold in 31 countries[44] - The company is focusing on channel expansion and enhancing its sales team to boost market penetration[69] - The company plans to further explore international market opportunities alongside domestic growth strategies[69] - The company aims to strengthen cooperation with leading clients globally and promote its products in Europe, Latin America, and Asia-Pacific regions[121] - The company is focusing on market expansion strategies to increase its footprint in both domestic and international markets[162] - The company is exploring potential mergers and acquisitions to bolster its market position and enhance its product portfolio[162] - Market expansion plans include entering two new international markets by Q2 2024, targeting a 15% increase in market share[185] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[188] - The company plans to enter two new international markets in the upcoming year, targeting a revenue contribution of $100 million[200] Product Development and Innovation - Six products have submitted registration materials to the National Medical Products Administration, including the Cratos® branched aortic stent and delivery system[41] - The company has submitted registration materials for the Vflower® venous stent and delivery system, and the Vewatch® inferior vena cava filter is in the pre-market clinical implantation stage[42] - The company is focused on collecting clinical data for its products in the European market and promoting innovative products for clinical trials in Europe and Japan[121] - The company aims to build a competitive product portfolio in the peripheral vascular field through independent research and development as well as mergers and acquisitions[178] - New product launches included two innovative medical devices, expected to contribute an additional $50 million in revenue[188] Corporate Governance and Management - The company is committed to improving its governance structure and decision-making mechanisms to ensure compliance with relevant laws and regulations[117] - The company has established a strong core professional team through optimized human resource management, ensuring sustainable development[46] - The company has revised its investor relations management system to enhance communication channels with investors, including performance briefings and direct interactions[148] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 15.08 million RMB[175] - The total remuneration for core technical personnel at the end of the reporting period was 4.78 million RMB[175] Financial Outlook and Projections - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming for $625 million[200] - The company provided an optimistic outlook for Q4 2023, projecting revenue growth of 20% to 25%[185] - The company has set ambitious performance guidance for the upcoming fiscal year, anticipating significant revenue growth driven by increased market penetration and product innovation[162] Operational Efficiency and Cost Management - The company reported a gross margin of 60%, maintaining strong profitability despite increased operational costs[185] - The management emphasized a commitment to sustainability, with plans to reduce carbon emissions by 25% by 2025[185] - The company plans to implement cost-cutting measures, aiming to reduce operational expenses by 15% over the next fiscal year[197] - Overall operational efficiency improved, with a reduction in costs by 5%, leading to higher profit margins[200]

Investment Rating - The report maintains a "Buy" rating for the company [3][25]. Core Insights - The company has rapidly promoted new products and advanced its R&D pipeline, leading to significant revenue and profit growth in 2023 [4][5]. - The company achieved a revenue of 1.187 billion RMB in 2023, a year-on-year increase of 32%, and a net profit of 492 million RMB, up 38% year-on-year [5]. - The company is expanding its international business, with revenue from overseas operations reaching 82 million RMB, a 56% increase year-on-year, and currently selling in 31 countries [6][13]. Summary by Sections Performance Overview - In Q4 2023, the company reported a revenue of 299 million RMB, a 29% increase year-on-year, and a net profit of 104 million RMB, up 86% year-on-year [5]. - The company’s core business segments showed strong growth, with a 28% increase in aortic stent revenue (940 million RMB), a 55% increase in intraoperative stent revenue (132 million RMB), and a 49% increase in peripheral and other business revenue (115 million RMB) [6][13]. Profitability and R&D - The overall gross margin for 2023 was 76.5%, an increase of 1.3 percentage points, while the net margin reached 41.0%, up 1.8 percentage points [18]. - R&D investment totaled 260 million RMB, a 51.2% increase year-on-year, accounting for 21.9% of revenue [18]. Cash Flow and Dividend Policy - The company generated a net operating cash flow of 558 million RMB in 2023, a 67.3% increase year-on-year [27]. - A dividend distribution plan was announced, with a total cash dividend of 248 million RMB, representing 50.4% of the net profit for the year [27]. Future Outlook - The company is expected to continue its growth trajectory, with projected net profits of 639 million RMB, 816 million RMB, and 1.066 billion RMB for 2024, 2025, and 2026, respectively, reflecting year-on-year growth rates of 30%, 28%, and 31% [6][10].

KPMG Huazheri LLP 8th Floor. KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 +86 (10) 8518 5111 Fax Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码:100738 电话 +86(10)8508 5000 传真 +86(10) 8518 5111 网址 kpmg.com/cn 审计报告 毕马威华振审字第 2403848 号 上海微创心脉医疗科技 (集团) 股份有限公司 自 2023 年 1 月 1 日 至 2023 年 12 月 31 日止年度财务报表 上海微创心脉医疗科技 (集团) 股份有限公司全体股东： 一、审计意见 我们审计了后附的上海微创心脉医疗科技 (集团) 股份有限公司 (以下简称 "心脉医疗")财 务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润 表、合 ...

上海微创心脉医疗科技 (集团) 股份有限公司 于 2023 年 12 月 31 日 内部控制审计报告 , KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 +86 (10) 8518 5111 Fax Internet kpma.com/cn 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化可 能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结果推 测未来内部控制的有效性具有一定风险。 第1页,共2页 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码 : 100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 内部控制审计报告 毕马威华振审字第 2403850 号 上海微创心脉医疗科技 (集团) 股份有限 ...

上海微创心脉医疗科技（集团）股份有限公司 2023 年度独立董事述职报告（付荣） 本人作为上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"） 的独立董事，严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公司 独立董事管理办法》、《上海证券交易所科创板股票上市规则》等法律法规及《公 司章程》、《独立董事工作制度》等规定，本着认真负责的态度，忠实勤勉的履行 独立董事的义务和职责，积极参加公司 2023 年召开的股东大会、董事会及董事 会各专门委员会等相关会议，认真审议董事会各项议案，对公司相关重大事项均 发表了独立意见，充分发挥了作为独立董事的专业优势及独立作用，现将 2023 年度主要工作情况报告如下： 一、本人基本情况 （一）个人工作履历、专业背景以及兼职情况 付荣女士，博士研究生学历。1986 年 8 月至 1994 年 11 月，担任哈尔滨铁 路运输中级法院经济审判庭助理审判员；1994 年 11 月至 1999 年 8 月，担任哈 尔滨铁路局工业总公司干事；2013 年 4 月至 2016 年 7 月，担任北京市炜衡律师 事务所上海分所兼职律师；2016 年 7 月至 2017 年 ...

中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 2023 年度持续督导工作现场检查报告 上海证券交易所： 根据《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监 管指引第11号——持续督导》等有关法律、法规的规定，中国国际金融股份有限 公司（以下简称"保荐机构"、"中金公司"）作为正在履行上海微创心脉医疗科技 （集团）股份有限公司（以下简称"心脉医疗"、"公司"）持续督导工作的保荐机 构，对公司2023年1月17日至2023年12月31日期间（以下简称"本持续督导期间") 的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （五）现场检查内容：公司治理及内部控制、信息披露、独立性、与关联方 的资金往来、募集资金使用情况、关联交易、对外担保、重大对外投资、公司经 营状况等。 （六）现场检查手段：对公司副总经理兼董事会秘书、财务总监及有关人员 进行访谈；查看公司主要经营、管理场所；查阅并取得公司公告、公司治理文件、 重大合同、公司定期报告等文件；查阅并取得公司募集资金使用凭证等原始凭证、 募集资金专户银行对账单等资料；查阅公司本持续督导期 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2024-016 上海微创心脉医疗科技（集团）股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 4 月 18 日 13 点 30 分 召开地点：上海市浦东新区康新公路 3399 弄 25 号楼 9 层公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 4 月 18 日 至 2024 年 4 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 1、 说明各议案已披露的时间和披露媒体 本次提交股东大会审议的议案，已经公司第二届董事会第二十五次会议及第二届 监事会第二十一次会议审议通过。具体内容详见公司于 2024 年 3 月 28 日刊载于 上海证券交易所网站（www.sse.co ...

中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 2024 年度日常关联交易预计的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为上海微创心 脉医疗科技（集团）股份有限公司（以下简称"心脉医疗"或"公司"）持续督导的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 5 号—— 交易与关联交易》等相关法律、法规和规范性文件的规定，对公司 2024 年度日常关联 交易预计事项进行了核查，具体情况如下： 一、日常关联交易基本情况 （一）本次日常关联交易预计金额和类别 结合公司业务发展及生产经营情况，公司 2024 年年度日常性关联交易预计额度， 合计不超过 10,197.71 万元，情况如下： 单位：万元 | 交易类别 | | | 占同类 | 本年年初 至 | 2024 | | | 本次预计额度 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 关联人 | 年度 2024 | 业务比 | ...

上海微创心脉医疗科技（集团）股份有限公司 关于 2023 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利 30 元（含税），每 10 股派送 红股 4.9 股（含税），不进行资本公积金转增股本。 证券代码：688016 证券简称：心脉医疗 公告编号：2024【- 013】 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配 总额不变，相应调整每股分配比例；同时拟维持送股总额不变，相应调整每股送 股比例，并将另行公告具体调整情况。 一、利润分配方案内容 经毕马威华振会计师事务所（特殊普通合伙）审计，截至2023年12月31日， 公司期末可供全体股东分配的未分配利润为1,095,224,845.51元人民币。经董事会 决议，公司2023年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。 本次利润分配方案如下： 公司拟以实施2023年度权 ...

2023 年度社会责任报告 远景 VISION 建设一个以人为本的全球领先新兴高科技医疗集团 Building a globally leading group of people centric enterprises of emerging medical technologies 使命 MISSION 为治疗血液循环疾病提供可及性真善美全医疗方案 To provide trustworthy and universal access to state-of-the-art total solutions to vascular circulatory diseases 价值观 VALUES | 质量 诚信 责任 效率 创新 争先 敬业 协作 | | --- | | OUALITY INTEGRITY ACCOUNTABILITY EFFICIENCY INNOVATION ASPIRATION DEDICATION COLLABORATION | 上 海 微 创 心 脉 医 疗 科 技 （ 集 团 ） 股 份 有 限 公 司 Shanghai MicroPort Endovascular MedTech ...